Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency

Inotersen MAA to be reviewed under EMA Accelerated Assessment program CARLSBAD, Calif. , Nov. 3, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for